Caricamento quotazioni...
Previsioni
| Acquista |
0 |
| Mantieni |
5 |
| Vendi |
0 |
Notizie Vai al feed delle notizie
Silverback Therapeutics hits 52-week high after strong price surge
Shares of Silverback Therapeutics reached a new 52-week high at $18.59, marking a year-over-year increase of 112.46%. The biotechnology company is benefiting from investor optimism, progress in its clinical pipeline, and a solid financial position. Analysts see further upside potential, while the company's market capitalization now stands at $1.81 billion. » Altro su de.investing.com
Safety Shot completes acquisition of Yerbae Brands and expands product portfolio
Safety Shot, Inc. has completed the acquisition of Yerbae Brands Corp. through a court-approved plan of arrangement. Following the transaction, Safety Shot shareholders hold approximately 81.64% and former Yerbae shareholders about 18.36% of the merged company. Safety Shot also plans to expand its product portfolio to include nootropics and sleep aids, and has entered into a debt settlement agreement with Silverback Capital Corporation. » Altro su de.investing.com
Dati finanziari dell'azienda
| (EUR) | giu 2026 | |
|---|---|---|
| Ricavi | 29,49 Mln | 121,16% |
| Utile lordo | 0 | - |
| Utile netto | -54,62 Mln | 43,44% |
| EBITDA | -53,86 Mln | 42,32% |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 475,08 Mln € |
Numero di azioni | 93,77 Mln |
Massimo/minimo a 52 settimane | 6,51 € - 2,42 € |
| Dividendi | No |
Beta | 0,00 |
Rapporto P/E | -2,70 |
Rapporto PEG | 0,03 |
Rapporto P/B | 46,75 |
Rapporto P/S | 5,00 |
Profilo aziendale
Silverback Therapeutics, Inc. ist ein biopharmazeutisches Unternehmen, das gewebebezogene Therapeutika für die Behandlung von chronischen Virusinfektionen, Krebs und anderen schweren Krankheiten entwickelt. Das Unternehmen bietet SBT8230 zur Behandlung chronischer Hepatitis-B-Virusinfektionen an, indem es eine antivirale Immunantwort durch gezielte TLR8-Aktivierung in der Leber auslöst. Silverback Therapeutics, Inc. wurde im Jahr 2016 gegründet und hat seinen Hauptsitz in Seattle, Washington.
| Nome | SILVERBACK THERAP. -,0001 Aktie |
| CEO | Peter A. Thompson |
| Sede centrale | Seattle,
wa Stati Uniti |
| Sito web | |
| Settore | Materiali |
| Industria | Prodotti chimici |
| Quotazione in borsa | 03/12/2020 |
| Dipendenti | 90 |
Deep Dive
Simboli di borsa
| Borsa | Simbolo |
|---|---|
NASDAQ | SBTX |
NASDAQ | SPRY |
Scopri gli asset
Gli azionisti di SILVERBACK THERAP. -,0001 Aktie investono anche nei seguenti asset
